(NAAC Accredited ‘A’ grade)

Slides:



Advertisements
Similar presentations
Week 10: Leukemia AML ALL FAB classification WHO classification
Advertisements

TA OGUNLESI (FWACP)1 CHILDHOOD LEUKAEMIA. TA OGUNLESI (FWACP)2 LEUKAEMIA Heterogenous group of malignant disorders Characterised by uncontrolled clonal.
Acute Promyelocytic Leukemia
Approach to Acute Leukemia
MALIGNANCIES OF THE HAEMAPOIETIC STEM CELL. Haemapoietic Stem Cell are pluripotent and give rise to all of the haemopoietic cell under the action of cytokines.
Acute leukemia Mohammed Al-matrafi.
Introduction To Haematological Malignancies
LEUKEMIA—HEMATOLOGY {S1}
Leukemias.
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood.
ACUTE MYELOID LEUKEMIA Irit Avivi
Leukemia Maturation of Myeloid Cells Dr. Rania Alhady.
Identification and Diagnosis of the Acute Leukemias
LEUKEMIAS Dr Mehboob Khan Pathologist
Acute leukemia Aggressive malignant hematopoietic disorders
Chapter 25: Acute Lymphoblastic Leukemia. Causes a wide spectrum of syndromes – From involvement of bone marrow and peripheral blood(leukemias) to those.
Acute Myeloid Leukemias (AML)
The acute Leukemias are clonal hematopoietic malignant disease that arise from the malignant T r a n s f o r m a t i o n of an early Hematopoietic stem.
Acute Leukemia: Clinical Cases and Correlates Daniel A. Nikcevich, MD, PhD Duluth Clinic Cancer Center May 13, 2008.
Hematopoietic and Lymphoid Neoplasm Project 1. Acknowledgments American College of Surgeons (ACOS) Commission on Cancer (COC) Canadian Cancer Registries.
Acute Leukemia and the FLT3 Receptor B y: Betty Sa’ Mentor: Dr. Govind Bhagat Site: Columbia University Vanderbilt Clinic.
Acute promyelocytic leukemia (APL) From the worst to the best prognosis MUDr. Petr Pavlíček Internal Hematological Clinics FNKV and 3LF UK in Prague.
Case Study MICR Hematology Spring, 2011 Case # 5 Hee Jin Kim, Hooman Nikizad and Arthur Omuro.
Myelodysplastic Syndrome (MDS)
The myelodysplastic syndromes (MDS) Aquired Clonal disease of BM. comprise a heterogeneous group of malignant stem cell disorders characterized by : 1.
MLAB HEMATOLOGY KERI BROPHY-MARTINEZ Myelodysplastic Syndromes.
MOLECULAR GENETICS and LEUKEMIA Clive S. Zent M.D. Division of Hematology/Oncology.
4th Year Medical Student KAU
Hematology and Hematologic Malignancies
Chronic leukemia 1. Chronic Lymphocytic leukemia (CLL) * Definition: Chronic neoplastic disorder characterized by accumulation of small mature-looking.
Heterogeneous group of hematopoietic neoplasms Uncontrolled proliferation and decreased apoptotic activity with variable degrees of differentiation Composed.
Leukaemias. Leukaemias: Malignant Disease of WBC Forming tissue or other hemopoietic elements: Lymphoblastic (ALL) Lymphoblastic (ALL)Acute Myeloid (AML)
Acute myeloid leukemia
MLAB 1415: Hematology Keri Brophy-Martinez
MLAB Hematology Keri Brophy-Martinez
Acute Leukemia Kristine Krafts, M.D..
LEUKEMIA Dr. Omar Alshaer. Acute Leukemia.
AML Clinical Presentation. Clinical Presentation: Symptoms Fatigue (50%) Anorexia and weight loss Fever with or without an identifiable infection (10%)
Hematology There are four lectures: 1.Acute leukemias (2 hours). 2.Chronic leukemias (2 hours).
SH/EAHP Workshop 2013 Case 93 Winnie Wu, M.D. Sheeja Pullarkat, M.D.
Society for Hematopathology/ European Association for Haematopathology Case 211 Rachel Ochs, MD Adam Bagg, MD Hospital of the University of Pennsylvania.
Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw 
Acute Leukemia Kristine Krafts, M.D..
Blood Biochemistry BCH 577
Acute myeloid leukemia
Acute Myeloid Leukemia
LEUKEMIAS H.A. MWAKYOMA, MD.
CLINICAL PROGRESSION INTRODUCTION METHOD CONCLUSION REFERENCES
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
MLAB Hematology Keri Brophy-Martinez
FLT3 Internal Tandem Duplication(ITD) mutation in Acute Myeloid Leukemia and its clincopathological correlation – Study from a tertiary care centre in.
Chronic Leukaemias Heterogeneous group of hematopoietic neoplasms
Leukemias.
HS 4160 Critical Scientific Analysis
17 Chapter 17: Chromosome 17 Nucleus 48,473 bp 882 aa RARA Cytoplasm
Misleading acute promyelocytic leukemia morphology
Leukemia Case 1.
Margaret L. Gulley, Thomas C. Shea, Yuri Fedoriw 
Acute Myeloid Leukemia
Case Study ….
Case:2 leukemia دينا نعمان جرادة جيهان ايمن مقاط.
Acute leukemia.
Diagnostic Hematology
Myelodysplastic syndromes
Case study A 36-year-old woman presented with a two-month history of increasing fatigue and abdominal fullness with accompanying loss of appetite. There.
Acute Leukemia Dr. Noha Noufal.
Jianbo Song, Danielle Mercer, Xiaofeng Hu, Henry Liu, Marilyn M. Li 
Neoplastic disorder.
CHRONIC LEUKEMIA BY: DR. FATMA AL-QAHTANI CONSULTANT HAEMATOLOGIST
MYELOID LEUKEMIAS Dr. B.V.Vydehi M.D PROFESSOR OF PATHOLOGY
Presentation transcript:

(NAAC Accredited ‘A’ grade) “Molecular characterization of t(15;17) in FAB classified M3 Acute Myeloid Leukemia patients” (NAAC Accredited ‘A’ grade) Radha Rathee Research Scholar, Deptt. of Genetics, M.D.U. Rohtak, Haryana Dr. Minakshi Vashist Professor and Head, Deptt. of Genetics, M.D.U. Rohtak, Haryana

Leukemia: “White blood” – leucos/aemia 1827 Alfred Velpeau 1845 JH Bennett – patients with enlarged spleens and changes in the colour of the blood – “Leucocythaemia” 1856 Virchow observed the white cells with a microscope – “Leukemia” 28/04/2017

Figure-Development of acute myeloid leukemia. Classification: Acute Chronic Myeloid Lymphoid Figure-Development of acute myeloid leukemia.

Acute Myeloid Leukemia Characterized by immature or undifferentiated hematopeitic cells, i.e. blast cell. Onset is rapid and abrupt Auer rods in M2, M3, M4 Thrombocytopenia Anemia >20% blasts in BM

Clinical Features: Symptoms Pallor and Purpura Skin Infiltration Gum Infiltration Pallor and Purpura Symptoms Skin Infiltration Hyphaema

Insidious nonspecific onset Pallor due to anemia Febrile due to ineffective WBC Petechiae/Pachy skin due to thrombocytopenia Mucus membrane and gum bleed in M4 and M5 subtype

Risk factors for acute leukemia: Ionizing radiation like X-rays, electromagnetic radiations Unsubscribed drugs intake during pregnancy Environmental factors like Chemicals exposure (Pesticides containing benzene, formaldehyde etc.) Genetic history Immunologic factors Viral agents

Translocation (15;17) Acute promyelocytic leukemia (APL or AML-M3) APL is subtype of Acute myeloid leukemia and leads to disseminated intravascular coagulation and death when not diagnosed and treated. More than 99% of APL patients harbor a translocation between chromosomes 15 and 17, which fuses the retinoic acid receptor alpha (RARA) gene on chromosome 17 with the PML gene on chromosome 15. The presence of this translocation is necessary for response to all-trans-retinoic acid and arsenic trioxide.

French American British (FAB) Classification of AML: French American British classified AML into 8 different classes depending upon presence of blast cell and their maturity. M0 -- Undifferentiated AML M1 -- AML without maturation M2 -- AML with maturation M3 -- Acute Promyelocytic Leukemia M4 -- Acute Meylomonocytic Leukemia M5 -- Acute Monocytic Leukemia M6 -- Erythroleukemia (DiGuglielmo’s) M7 -- Megakaryoblastic Leukemia

CYTOGENETICS/WHO Classification: WHO classified AML on the basis of chromosomal anomalies. Different categories are as follows: AML with characteristic genetic abnormalities: which includes translocations [t(8;21)], [t(15;17)], and Inversion [inv(16)]. II. AML with multilineage dysplasia: It includes patients having a prior myelodysplastic syndrome (MDS) or myeloproliferative disease (MPD) that transforms into AML. III. AML and MDS, therapy-related: This category have patients who had prior chemotherapy and/or radiation and subsequently developed AML or MDS. IV. AML not otherwise categorized: It includes subtypes of AML that do not fall into the above categories.

FAB vs WHO: Classifications of AML: WHO criteria Clinical features Morphology Immunophenotyping Cytogenetic features FAB criteria Morphology Cytochemistry

OBJECTIVES: AML PATIENTS To identify patients of AML with the help of FAB classification. To find out the ploidy level in M2 subtype of AML patients. Molecular characterization of structural anomalies in M2 subtypes of AML patients.

TECHNIQUES HEMATOLOGICAL ANALYSIS: 1. Hemoglobin Estimation 2. White blood cell count 3. Leishman’s staining 4. Sudan Black B Staining HUMAN CYTOGENETICS: Lymphocyte culture G – banding Karyotyping MOLECULAR ANALYSIS (RT- PCR): Rna isolation from human peripheral blood Agarose gel electrophoresis

Hematological analysis: 1. Hemoglobin Estimation: 2. White blood cell count:

Blast cells morphology 3. Leishman’s staining 4. Sudan Black B Staining

Whole blood culture and harvesting

46,XX, t(8;21)(q22;q22)

RNA Isolation

Molecular Analysis Isolation of RNA c DNA synthesis Reverse transcript PCR Agose gel electrophoresis Photography (View the gel under UV light)

Outer AML1-primer sequences 5′-AGCCATGAAGAACCAGG-3′ Reverse transcriptase PCR with following primer sequences was conducted. Outer AML1-primer sequences 5′-AGCCATGAAGAACCAGG-3′ Outer MTG8-primer 5′-AGGCTGTAGGAGAATGG-3′ Nested AML1-primer 5′-TACCACAGAGCCATCAAA-3′ Nested MTG8-primer 5′-GTTGTCGGTGTAAATGAA-3′ Translocation t(8;21) was found in 18(9.5%) patients. The translocation t(8;21) alone was found in 14 cases. The FAB subtype of these patients was M2 with SR of 1.25:1. In 4 cases translocation t(8;21) was found together with other abnormalities including trisomy of chr. 8 (n=1), chr. 22 (n=2) and deletion 5 (n=1). Mean values of hemoglobin was 6.4gm/dl (range; 4.2-9.5gm/dl), W.B.C count 7.4X109/L (range; 3.1-16X109/L) and platelet count was 51X109/L (range; 25-78X109/L).

RNA Extraction and quantification RNA was isolated from whole blood using Trizol-method of RNA extraction. Purity of RNA was checked at the OD 260/OD 280. All the samples were found to be in desirable reference ratio 1.9 to 2.0. The purified RNA samples were stored in elution buffer at -800C. Sample ID User Sample Type Timestamp Conc. Unit A (260 nm) A (280 nm) 260 / 280 t(8;21) M2 Radha Rathee RNA 6/19/2014 12:44:38 PM 49.665 ng/μl 0.992 0.480 2.064 Figure- Estimation and quantification of RNA sample of FAB-M2 subtype purity by using Nanodrop method.

RT-PCR amplified product Figure-: Gel image of RT-PCR amplified product for primer PML-RARA. Lane 1-10 amplified product, Lane 11negative control and Lane 12 ladder of 1000bp.

The results of the molecular analysis using RT-PCR of 76 patients were compared with cytogenetics as well as FAB classification. It was found that there were 18 cases of (10 male and 8 female) of AML1/MTG8 [fusion transcript of t(8;21)(q22;q22)] Reverse transcriptase PCR analysis with the help of AML1/MTG8 revealed fusion transcript of t(8;21)(q22;q22) in 18 patients having FAB classification M2 subtype. In two patients (nos. 17 and 18) the t(8;21) was not detected by cytogenetics: patient 17 was karyotyped as t(8;9); patient 18 had a normal karyotype. Similarly, in three patients (nos. 1, 2 and 3), cytogenetic analysis revealed additional chromosomes no. 8 (+8), chromosomes no. 22(+22) and deletion of chr. 5 (-5) in addition to translocation t(8;21). In 12 patients standard cytogenetics did not revealed any other additional chromosomal aberrations.

Translocation detected by Cytogenetics and RT-PCR. Patient Age/Sex FAB/FCM PCR result Cytogenetics result 1 23/M M3 PML/RARa 46,XY,t(15;17)(q22;q12),+22 2 41/M 46,XY,-5,t(15;17)(q22;q12) 3 29/F 46,XX,t(15;17)(q22;q12),+22 4 36/F 46,XX,t(15;17)(q22;q12) 5 39/F 6 38/F 7 42/F 47,XX,t(15;17)(q22;q12) 8 43/F 48,XX,t(15;17)(q22;q12), 9 47/M 45,XY, t(15;17)(q22;q12) 10 45/M 46,XY,t(15;17)(q22;q12)

SUMMARY & CONCLUSIONS One of the molecular-cytogenetic markers associated with a favorable prognosis in AML-M3 is t(15;17). We found t(15;17)/PML-RARA in 4.11% of AML cases.

Future Prospectus The challenging questions with regard to t(15;17) involved leukemogenesis remain as: what are the critical target genes regulated by retinoic acid receptor alpha (RARA) gene on chromosome 17 with the PML gene on chromosome 15. What are the molecular pathways that cooperate with PML/RARA in promoting the oncogenesis of hematopoietic cells? The massive amount of new information about the human and mouse genomes and new technology development will greatly enhance our ability to address these interesting questions.

MAHARSHI DAYANAND UNIVERSITY, Rohtak-124001, Haryana THANK YOU